Skip to main content
Featured News, Sidebar Featured News, Sue Blalock
Brittany Jennings
July 3, 2020

The UNC Eshelman School of Pharmacy would like to send best wishes to professor Susan Blalock, Ph.D., MPH, who retired from the School on June 30.

Blalock has worked for the University of North Carolina at Chapel Hill since 1982, and at the UNC Eshelman School of Pharmacy for the past 18 years. Most recently, she served as a professor in the School’s Division of Pharmaceutical Outcomes and Policy (DPOP), where she vice chaired from 2011-17.

Blalock is a behavioral scientist with expertise in patient and public health education. She is particularly interested in risk communication and the impact of pharmaceutical care, including patient education and counseling, on patient health outcomes. Her research focuses primarily on the prevention and treatment of rheumatoid arthritis, osteoarthritis, and osteoporosis. Her most recent work includes studies evaluating the impact of community pharmacy-based illness prevention and disease management programs.

Throughout her career, Blalock said she is most proud of being chair of the U.S. Food and Drug Administration’s Risk Communication Expert Advisory Committee; writing the book “Making Meaning of Data in Pharmaceutical and Clinical Research,” that was published by the American Pharmacists Association in 2019; and helping to create STEADI-Rx, a community pharmacy-based falls prevention program.

“I want to thank Susan for her selfless service to the Division of Pharmaceutical Outcomes and Policy. She helped build our division into one of the premier pharmaceutical outcomes divisions in the country,” said Betsy Sleath, chair of DPOP. “Sue was instrumental in helping our division expand to having outcomes faculty on both the Chapel Hill and Asheville campuses. She is a wonderful mentor to junior faculty and students.  She is an outstanding scientist with over 150 peer-reviewed publications and numerous book chapters. She received funding from several different agencies, including the Patient-Centered Outcomes Research Institute, the Centers for Disease Control, the National Institutes of Health, and the Arthritis Foundation. We will miss her, but we are happy she will continue with us as a professor emeritus.”

Related Articles

View All
Comments are closed.